Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Human anti-viral drug offers hope for cats
Bubba, one of the study cats, was diagnosed with abdominal non-effusive FIP. One week into the 12-week treatment course his owner reported he was ‘eating on his own, alert, energetic and playful.’

Field trial shows positive results in treating cats with FIP

An anti-viral drug used in human medicine has shown great promise in the treatment of a devastating infectious disease of cats.

One of the most promising treatments for emerging exotic viruses in humans is GS-5734. Studies have proved it to be effective in preventing ebola in rhesus monkeys and inhibiting coronaviruses in tissue culture and mouse model infections.

New research by the University of California (UC) Davis suggests the treatment could also offer hope to cats with feline infectious peritonitis (FIP), which is estimated to kill up to 1.4 per cent of cats around the world.

Initial studies studies by UC Davis found that GS-441524, which is the parent nucleoside of GS-5734, was highly effective against FIP. A field trial was subsequently carried out involving 26 cats with naturally-occurring FIP, which received at least 12 weeks of treatment.

The findings have been published in the Journal of Feline Medicine and Surgery (JFMS).

Researchers reported a ‘dramatic’ clinical response. Fever usually resolved in 12-36 hours and marked improvements were seen in appetite, activity levels and weight gain. In cats with the more common effusive or ‘wet’ form of the virus, abdominal effusions quickly disappeared from around day 10-14 after starting treatment.

Older cats, or those with non-effusive, or ‘dry’ FIP responded just as well to treatment as young cats and those with effusive FIP.

Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP and another to unrelated heart disease. In total, 18 of the cats received just one round of treatment, while the remaining eight suffered relapses of the disease. These were successfully treated with a second round of treatment at a higher dose. In two cases, a third round of treatment was needed.

Traditionally the prognosis for cats infected with FIP were bleak. In a review paper published in JFMS 10 years ago, the lead author for this study, Professor Niels Pedersen wrote: ‘No treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of the disease in days, weeks or months.’

However, following this latest study, as he approaches the end of his career, Prof Pedersen said: “FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP.”

However, he cautioned that the field trial was for proof-of-concept and cannot yet be translated into commercially available drugs. He warned that the hope provided by these initial trials has increased the desperation of owners to acquire these drugs on the black market.

He added: “As eventful as these discoveries may be, there is still much more about FIP to discover.”

Image © Adel Gastle

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
New guidance for antibiotic use in rabbits

New best practice guidance on the responsible use of antibiotics in rabbits has been published by the BSAVA in collaboration with the Rabbit Welfare Association & Fund (RWA&F).

The guidance is free and has been produced to help veterinary practitioners select the most appropriate antibiotic for rabbits. It covers active substance, dose and route of administration all of which are crucial factors when treating rabbits owing to the risk of enterotoxaemia.

For more information and to access the guide, visit the BSAVALibrary.